drugset / Trial / NCT00158704

Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection.

NCT00158704

Terminated 400 enrolled Gilead Sciences
Non-randomizedOpen-labelTreatment

Summary

Provide adefovir dipivoxil (Hepsera) 10 mg once daily to patients with chronic hepatitis B virus (HBV) infection who have completed a Gilead-sponsored study of adefovir dipivoxil and require continued access to adefovir dipivoxil.

Timeline

Start
2002-01
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Adefovir dipivoxil Small molecule 10 mg